Life Sciences

The platform that made single-cell and spatial transcriptomics routine, through Chromium, Visium and Xenium instruments and consumables. Single-cell data has become a standard component of target-discovery and mechanism-of-action packages presented to partners and investors.

A rare combination of large-scale diagnostics — core laboratory, molecular, point-of-care and rapid testing — with cardiovascular devices, continuous glucose monitoring and nutrition. The most direct large-cap comparator for any diagnostics company, and a benchmark for point-of-care and CLIA-waived commercialization.

Immunology, oncology, neuroscience and aesthetics, and the industry's most-studied case of managing loss of exclusivity on a single dominant product through follow-on assets and acquisition. Its playbook is the reference case for any company facing a patent cliff.

The medical technology industry association, publisher of the AdvaMed Code of Ethics on interactions with healthcare professionals — the compliance baseline most device companies formally adopt — and the sector's principal voice on FDA policy and reimbursement.

One of the original biotechnology companies, with large-molecule manufacturing depth, a significant biosimilars portfolio and programs across inflammation, oncology, cardiovascular and obesity. Its biologics process-development capability is a genuine structural moat rather than a portfolio claim.

An Austin molecular-diagnostics company known for genetic testing kits and the Armored RNA and reference-material product lines used as quality controls in other laboratories assays. Acquired by Bio-Techne in 2021 and now positioned as a Bio-Techne brand, though asuragen.com remains live as its own site. Ownership verified; current Austin site scope not independently confirmed.

UT Austin's deep-technology incubator, operating verticals that have included bioscience and health alongside energy, water, food and mobility. Its role is company formation and early venture development around university research, making it a standard first stop for an Austin science founder. Program vertical names have changed over time and current bioscience-track structure should be confirmed directly.

Supplies much of the world's specimen collection, injection, infusion and laboratory automation infrastructure alongside microbiology and molecular diagnostics. Because BD products sit in the pre-analytical step of nearly every test, compatibility with BD collection systems is a practical requirement for new assays.

The most widely adopted modern electronic lab notebook and R&D data platform for biotechnology, covering molecular biology design, registry, inventory, workflows and analysis. For many biotechs it is the system of record for the science itself, which makes migration off it extremely rare.

The largest biotechnology trade association, representing companies across therapeutics, agriculture and industrial biotech, and organizer of the BIO International Convention — the industry's principal partnering meeting, where a very large share of licensing conversations begin.

Interventional cardiology, electrophysiology, endoscopy, urology and neuromodulation devices, grown substantially through acquisition of clinical-stage device companies. One of the most active acquirers in medtech, which makes it both a competitor and a plausible exit for device startups.

The leading laboratory accreditation body, whose inspection checklists and proficiency-testing programs exceed the CLIA floor and are the de facto quality standard for clinical laboratories. CAP accreditation is what hospital customers and payers actually look for.

The dominant provider of research models, GLP safety assessment, discovery services and manufacturing quality control testing. A very large share of INDs filed in the US rest on data generated at Charles River, which makes its capacity and pricing a de facto industry constraint.

The CMS-administered federal program certifying laboratories that test human specimens, setting personnel, quality control and proficiency-testing requirements by test complexity. CLIA certification — and the separate FDA CLIA-waiver determination — determines where a test may legally be run, which directly sets its addressable market.

The NIH-maintained public registry and results database for clinical studies worldwide. Registration is legally required for many trials, which makes it the primary verifiable source for what a competitor is actually running, where, in what population and against what endpoint — the best free competitive-intelligence asset in the sector.

The highest-profile Texas biotechnology company, applying ancient-DNA sequencing, comparative genomics and multiplex gene editing to de-extinction and species-preservation programs, funded at multibillion-dollar valuations. Its scientific claims are actively contested by outside specialists and should be described as announced work rather than as settled results.

The Austin-headquartered state agency funding cancer research, prevention and company product development in Texas — established by constitutional amendment in 2007 and extended by voters in 2019 to a $6 billion total authorization. Its product-development awards are the single most important source of non-dilutive capital for a Texas life-science company, and its recruitment grants are why a large share of the state's principal investigators are here.

An operating company running a portfolio of life-science and diagnostics businesses including Cytiva, Beckman Coulter, Leica Biosystems, Molecular Devices, IDT and Cepheid. Its bioprocessing franchise sits directly in the biologics manufacturing chain, making it a structural supplier to the same companies it competes with in tools.

The first medical school built at a tier-one US research university in decades, opened in 2016, and the institution that gave Austin local capacity to host clinical trials, translational research and physician-scientist collaboration rather than referring it to Houston or Dallas. Its translational and health-innovation programs are the most direct academic partner for an Austin life-science company.

The company most transformed by incretin and GLP-1 medicines, with major franchises in diabetes, obesity, oncology, immunology and neuroscience. Its multibillion-dollar US manufacturing build-out is reshaping domestic sterile-injectable and API capacity for everyone.

The EU's centralized medicines regulator, publishing European Public Assessment Reports, scientific guidelines and safety communications. Divergence between FDA and EMA positions on the same dossier is common and is a substantive content topic rather than a technicality.

The biopharma trade publication read most closely by industry executives and investors, covering clinical readouts, regulatory decisions, financings and personnel moves. Coverage in Endpoints is a meaningful credibility signal and its archive is a reliable timeline source.

The authority that governs every claim a US life-science company makes — approving and clearing products, defining labeling, regulating prescription drug promotion through OPDP, publishing guidance, running inspections and issuing warning letters. Cite FDA guidance, the approved label and the agency's own databases; never characterize a designation as evidence of efficacy.

Daily coverage of biotech and medtech financings, clinical data, approvals, layoffs and deals, alongside Fierce Pharma and Fierce Medical Devices. The most widely scanned free trade source in the sector and a practical monitor for competitor activity.

An organism-engineering and automated-laboratory platform offering strain development, biosecurity monitoring and datapoints-as-a-service, plus contract lab automation. Also the sector's most public test of whether a horizontal biology platform can be a business rather than a service bureau.

One of the largest CROs, providing full-service clinical development, functional service provision, laboratory and commercialization services across all phases. Its scale in site networks and patient recruitment is what small sponsors are effectively buying.

The dominant supplier of next-generation sequencing instruments, flow cells and reagents, and the platform most clinical and research genomics is built on. Its razor-and-blade consumables model sets the cost floor for sequencing-based diagnostics; recent divestiture, geopolitical restrictions and new entrants have introduced real competitive pressure for the first time in a decade.

The largest combination of clinical research organization and healthcare data provider, running trials while also selling the prescription, claims and reference data that underpin most commercial analytics and market sizing in the industry. Competes across clinical operations, real-world evidence, and commercial and medical-affairs outsourcing simultaneously.

The international quality management system standard for medical devices, and the framework toward which FDA harmonized its own device quality regulation. Certification is a practical prerequisite for European market access and for most device manufacturing partnerships.

One of the most widely deployed laboratory information management systems in regulated environments, particularly in pharmaceutical QC and manufacturing laboratories where Part 11 compliance, instrument integration and long validation lifecycles dominate the selection decision.

Founded in Austin, Luminex built the xMAP bead-based multiplexing platform - which DiaSorin still markets as the most widely used multiplexing technology - along with the ARIES and VERIGENE molecular systems. It was acquired by Italian diagnostics company DiaSorin in 2021 and its product lines now sit inside DiaSorin, with luminexcorp.com redirecting to DiaSorin. Its Austin alumni network is the foundation of the local molecular-diagnostics talent pool. Parent-company status verified; current Austin site headcount not independently confirmed.

A leading clinical trial platform covering electronic data capture, randomization and trial supply, eCOA, imaging and synthetic control arms built from historical trial data. A very large proportion of industry-sponsored trials run on Medidata Rave.

One of the largest medical device companies in the world, spanning cardiovascular, neuroscience, surgical and diabetes portfolios. Its scale in hospital contracting and its installed base define the incumbency any device startup must argue against in a value-analysis committee.

A research-driven pharmaceutical company whose oncology franchise is the largest single revenue concentration in the industry, alongside vaccines and animal health. It also operates a large technology and business-services hub in Austin, making it one of the few global pharma names with a substantial local employment footprint. Its approaching loss of exclusivity is the single biggest driver of pipeline acquisition activity in the sector.

An mRNA platform company spanning respiratory vaccines, latent-virus vaccines, oncology and rare disease. Its post-pandemic contraction is also instructive — the sector's most-cited example of the difference between a platform and a product franchise.

The largest public funder of biomedical research in the world, operating through 27 institutes and centers, and the source of most SBIR/STTR life-science awards. NIH funding decisions shape what science exists to be commercialized, and RePORTER makes the entire grant landscape publicly searchable.

The century-old diabetes-care leader now central to the GLP-1 obesity market, with a century of insulin manufacturing depth and a large recent expansion of fill-finish capacity. Together with Lilly it absorbs a large share of global injectable manufacturing capacity, which affects availability for everyone else.

A clinical research organization with a notably deep regulatory consulting practice — including former agency reviewers — which makes it the CRO most often engaged for complex or first-in-class regulatory strategy rather than pure execution capacity.

One of the largest pharmaceutical companies globally, with a broad portfolio across vaccines, oncology, internal medicine, inflammation and immunology. Its post-pandemic revenue normalization and looming exclusivity losses have made it one of the sector's most aggressive business-development buyers.

The research-based pharmaceutical industry association, and publisher of the PhRMA Code on Interactions with Health Care Professionals, which most member companies certify compliance with and which functions as the practical rulebook for speaker programs, meals and educational support.

An antibody-discovery platform company with programs in ophthalmology, immunology, oncology and hematology, plus a large-scale human genetics sequencing effort. Its integrated discovery-to-manufacturing model is unusually vertically complete for a biotech.

The leading physics-based computational chemistry platform for molecular design, free-energy perturbation and virtual screening, licensed across large pharma while also running its own internal drug programs. The reference point for what computational design can and cannot yet claim.

Health, medicine and life-science journalism with a strong investigative and scientific-scrutiny orientation. STAT is where overstated efficacy claims and questionable trial conduct get examined publicly, which makes it both a citation source and a reason to keep promotional copy defensible.

Orthopedic implants, surgical equipment, neurotechnology and the Mako robotic-arm surgical platform. Its capital-equipment-plus-consumables model and surgeon-preference dynamics are the template for how high-value surgical devices are actually sold.

Acquired Shire in 2019, bringing rare-disease and plasma-derived therapy franchises with substantial Texas operations — including a large plasma-derived therapies manufacturing presence in the state. Listed here as the largest global pharma with meaningful Texas manufacturing rather than as an Austin-headquartered entity; specific Austin-site status is not independently confirmed.

The statewide trade association for healthcare and bioscience, headquartered in Austin on Brazos Street, advocating policy that promotes biomedical science, biotechnology, agriculture and medical device innovation in Texas. Its membership spans pharmaceutical and biotech companies, device manufacturers, academic institutions and economic development organizations, which makes it both the most direct policy channel for a Texas life-science company and a useful map of who is actually operating in the state. Note the current site is thbi.com; the former thbi.org domain is no longer controlled by the organization.

The largest life-science tools company in the world, spanning instruments, reagents and consumables, laboratory products, specialty diagnostics and — through Patheon and its biologics business — contract development and manufacturing. Nearly every life-science company is a Thermo Fisher customer, which makes it simultaneously the default supplier and the incumbent to displace in almost every tools or services category.

Silicon-based DNA synthesis producing genes, oligo pools, NGS target-enrichment panels and antibody libraries at costs that changed what a small team can attempt. A structural enabler of synthetic biology and of custom panel-based diagnostics.

Sets legally recognized quality standards for medicines, excipients and dietary supplements through the USP–NF compendia and supplies reference standards. Compliance with a USP monograph is enforceable under US law, making USP a regulator in practice as well as a standards body.

Home to molecular biosciences, chemistry, biochemistry, neuroscience and computer science at UT Austin, and the source of both the research inventions that become Austin spinouts and the technical hiring pool those companies draw from. The most important single talent pipeline in the local cluster.

The dominant industry-specific software vendor for life sciences, spanning CRM for field teams, regulatory information management, quality and document control, clinical data and medical affairs. Because Veeva Vault is where regulated content is approved and stored, its workflow effectively defines how promotional material gets reviewed.

Built a dominant franchise in cystic fibrosis through serial mechanism-based innovation, and has expanded into pain, kidney disease and gene-edited cell therapy. The clearest example in the industry of a company that made rare-disease specialization into large-cap scale.